Overview

Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment

Status:
Not yet recruiting

Trial end date:
2022-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to treat patients with retinal vein occlusion with standard of care anti-vascular endothelial growth factor therapy and to correlate levels of vascular endothelial growth factor in the anterior chamber fluid of the eye. This study will evaluate if measuring the vascular endothelial growth factor will help predict the timing of when anti-vascular endothelial growth factor therapy will be needed.

Phase:

Phase 4

Details

Lead Sponsor:

Wake Forest University Health Sciences

Treatments:

Aflibercept